Novartis
Novartis Licenses BeiGene’s Antibody for a Potential $2.8 Billion After Its Own Drug Disappoints
2021-12-21
Novartis Expands Optogenetics Portfolio By Acquiring Swiss Startup for an Undisclosed Amount
2021-09-21
After FDA Lifts Hold, Novartis to Proceed with Clinical Trials for Expensive Rare Disease Therapy
2021-08-04
FDA Approves Foundation Medicine’s Liquid Biopsy Test as Companion Diagnostic for Novartis’ Tabrecta
2021-07-18